1. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
   Giuseppe Bronte et al, 2014, Critical Reviews in Oncology/Hematology CrossRef
2. Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness
   R. E. Kast, 2015, SpringerPlus CrossRef
3. Maintenance therapy for advanced non-small cell lung cancer (NSCLC)
   Sophie Paget-Bailly et al, 2015, Cochrane Database of Systematic Reviews CrossRef